Stay updated on LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Sign up to get notified when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.

Latest updates to the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page
- Check4 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2 on the page.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedPage revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check40 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 in the page footer.SummaryDifference0.1%

- Check68 days agoChange DetectedUpdated the page to Revision 3.4.2. The government funding lapse notice and the prior Revision: v3.4.1 entry were removed.SummaryDifference0.4%

- Check75 days agoChange DetectedAdded a site-wide notice about government funding lapse and NIH open status. Updated the site revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check83 days agoChange DetectedUI and metadata changes include displaying the glossary option, adding 'No FEAR Act Data', and updating the Revision to v3.4.0, while removing the older items 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and the older Revision v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.